Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis

Withdrawn before enrolling · Not applicable

Conditions studied: Multiple Sclerosis, Relapsing-Remitting

In brief

This study is designed to compare two non-myeloablative conditioning regimens (combination of chemotherapy and immune specific proteins against immune cells) for relapsing remitting multiple sclerosis (RRMS). The two conditioning regimens are the most commonly used world wide in clinical practice for the treatment of multiple sclerosis (MS). The first investigational conditioning regimen is cyclophosphamide (chemotherapy) and rATG (rabbit anti-thymocyte globulin, a protein against immune cells). The second investigational conditioning regimen includes the same dose of cyclophosphamide (chemotherapy) and rituximab (a protein against immune cells). Both cyclophosphamide and either rATG or rituximab are given to kill immune cells that are thought to be causing MS, followed by return of one's own previously collected blood stem cells (autologous stem cell transplant) to hasten recovery. The goal of this study is to assess the difference of these treatments in terms of toxicity and efficacy.

Key facts

Study ID: NCT05482542
Run by: Scripps Health
People needed: 0
Starts: 2023-01-01
Expected to finish: 2027-07-01
Last updated by the study team: 2023-11-09

Who can join

Age: 18 and older, up to 58. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age 18-58 years old
MRI T2 hyperintense lesions with at least 1 lesion in two or more of the following locations: periventricular, cortical or juxtacortical, infratentorial, or 1 spinal lesion
Since diagnosis a new MRI T2 lesion or since diagnosis a gadolinium positive lesion and at least one T2 weighted lesion
RRMS with a history of:
2 or more "active flares" in the prior 12 months despite either copaxone or interferon; or
1 or more "active flares" in the prior year despite a 2nd or 3rd generation DMT; or
Active secondary progressive MS (aSPMS) with 2 or more gadolinium enhancing lesions with at least 1 gadolinium enhancing lesion > 5 mm in longest dimension within the last 9 months

You may not qualify if…

CIS- clinically isolated lesion
isolated optic neuritis
Primary progressive MS b) Nonactive SPSM (defined as no new or enhancing lesions in last 12 months)
spasticity or clinical stiffness of leg(s) unless there is documented new MRI enhancement within the past 12 months.
hyperreflexia or clonus
other immune neurologic disease such as NMO, CIDP, Stiff person syndrome, myasthenia gravis
genetic neurologic diseases such as CMT or spinal cerebellar degeneration
another autoimmune diagnosis such as systemic lupus erythematosus, systemic sclerosis, Behcets, or crohn's disease, etc (with the exception of hypo or hyperthyroidism or history of ITP or AIHA that is in remission)
insulin dependent diabetes mellitus
sickle cell disease
thalassemia major
porphyria
a current or prior cancer / malignancy except for cutaneous basal cell carcinoma or carcinoma in situ (completely excised)
Hepatic:
Liver function test (AST or ALT) > 2 x upper limit of normal or
bilirubin > 2.0 mg /dl
Pulmonary:
DLCO < 60% of normal or;
Asthma not easily corrected with bronchodilator therapy or;
Pulmonary artery hypertension (pulmonary artery systolic pressure (PASP) > 40 mmHg on echocardiogram or by cardiac catheterization a mean pulmonary artery pressure (mPAP) > 25 mmHg; a cardiac catheterization for pulmonary artery pressures is only performed if clinically indicated)
Renal:
creatinine > 2.0 mg/dl, or
nephrotic syndrome
Cardiac:
Acute myocardial infarction (AMI) within the last year, and if history of AMI not being approved by cardiology as low risk or not at increased risk for another AMI: or

Where it is running

Scripps Green Hospital — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.